Published in World J Gastroenterol on September 21, 2006
Clinical outcomes of no residual disease in the specimen after endoscopic resection for gastric neoplasms. Surg Endosc (2015) 0.82
Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer. Dis Markers (2014) 0.80
Association of Helicobacter pylori and iNOS production by macrophages and lymphocytes in the gastric mucosa in chronic gastritis. J Immunol Res (2014) 0.80
Secondary prevention of gastric cancer. Gut (2007) 0.78
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) 32.58
Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol (1996) 21.37
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res (1992) 12.77
The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 7.89
Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet (1997) 7.59
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum (1994) 7.37
A human model of gastric carcinogenesis. Cancer Res (1988) 6.52
Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol (1988) 3.67
Gastric dysplasia: the Padova international classification. Am J Surg Pathol (2000) 3.66
Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology (1994) 3.15
Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol (1994) 2.97
Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer (1994) 2.74
Gastric cancer in Colombia. III. Natural history of precursor lesions. J Natl Cancer Inst (1976) 2.14
Gastric cancer in Colombia. I. Cancer risk and suspect environmental agents. J Natl Cancer Inst (1976) 2.09
Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology (1972) 2.09
Diagnostic criteria for gastrointestinal carcinomas in Japan and Western countries: proposal for a new classification system of gastrointestinal epithelial neoplasia. J Gastroenterol Hepatol (2000) 2.01
Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther (2002) 1.94
Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer (1985) 1.89
Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut (1985) 1.64
The biological model of gastric carcinogenesis. IARC Sci Publ (2004) 1.53
The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J (1981) 1.52
Simple atrophic gastritis and gastric carcinoma. Gut (1971) 1.46
Sulphomucins and precancerous lesions of the human stomach. Histopathology (1980) 1.40
Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther (2002) 1.38
The long term outcome of gastric non-invasive neoplasia. Gut (2003) 1.37
Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample. Cancer (1983) 1.36
Development of adenocarcinomas in the stomach. Cancer (1986) 1.32
Staging and grading of chronic gastritis. Hum Pathol (2005) 1.31
Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev (1996) 1.25
Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol (2000) 1.24
Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol (1999) 1.24
Gastric dysplasia. Significance and pathologic criteria. Cancer (1984) 1.23
Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol (2000) 1.19
Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer (2000) 1.18
Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer (1998) 1.15
The sequelae and course of chronic gastritis during a 30- to 34-year bioptic follow-up study. Scand J Gastroenterol (1985) 1.14
Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis (2005) 1.07
Long-term observation of subjects with normal mucosa and with superficial gastritis: results of 23--27 years' follow-up examinations. Scand J Gastroenterol (1978) 1.07
Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy (1997) 1.03
Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry. J Pathol (1993) 1.01
Diagnosis of atrophic gastritis from a serum sample. Clin Lab (2002) 0.97
Precancerous lesions in two counties of China with contrasting gastric cancer risk. Int J Epidemiol (1998) 0.97
'Serological biopsy' in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol (2003) 0.95
Serum pepsinogen I and serum gastrin in the screening of atrophic pangastritis with high risk of gastric cancer. Scand J Gastroenterol Suppl (1991) 0.95
Gastric cancer in Colombia. II. Case-control epidemiologic study of precursor lesions. J Natl Cancer Inst (1976) 0.94
Diagnosis of gastritis by means of a combination of serological analyses. Clin Chim Acta (2002) 0.93
Chronic gastritis as a cancer precursor. Scand J Gastroenterol Suppl (1984) 0.92
The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl (2002) 0.91
Genetic etiology of gastric carcinoma: I. Chronic atrophic gastritis. Genet Epidemiol (1986) 0.91
Characteristics of gastric mucosa which precede occurrence of gastric malignancy: results of long-term follow-up of three family samples. Scand J Gastroenterol Suppl (1991) 0.88
Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. Histopathology (2001) 0.83
Dynamics of antral and fundal gastritis in an Estonian rural population sample. Scand J Gastroenterol (1977) 0.82
Grade of Helicobacter pylori colonisation, chronic gastritis and relative risks of contracting high gastric ulcers: a seven-year follow-up. Scand J Gastroenterol Suppl (1991) 0.82
Pepsinogen A/pepsinogen C or pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer? Ital J Gastroenterol (1991) 0.81
Gastritis and gastric cancer. Br Med J (1972) 0.80
Chronic gastritis profiles in sibs of probands calculated to carry a highly increased risk of gastric carcinoma. Scand J Gastroenterol Suppl (1991) 0.80
Sydney classification for gastritis. Lancet (1991) 0.80
Helicobacter pylori eradication and serum pepsinogens. Gut (1996) 0.79
Actual role of pepsinogen group I in the study of upper gastrointestinal diseases. Clin Biochem (1983) 0.78
Susceptibility to chronic gastritis in first degree relatives of gastric carcinoma patients. Effect of histological type of carcinoma and location of tumour. Ann Clin Res (1984) 0.76
Primary gastric MALT lymphoma: trivial condition or serious disease? Helicobacter (1997) 0.76
Serological tests to monitor treatment of Helicobacter pylori. Lancet (1992) 0.76
Age of gastric cancer patients and susceptibility to chronic gastritis in their relatives. A mathematical approach using Poisson's process and scoring of gastritis state. Scand J Gastroenterol (1973) 0.76
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol (2009) 3.29
A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology (2004) 2.70
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell (2005) 2.66
Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology (2008) 2.63
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother (2011) 2.16
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis (2004) 1.66
Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine (2004) 1.65
Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol (2008) 1.62
Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin Gastroenterol Hepatol (2010) 1.58
Barrett's epithelium after antireflux surgery. J Gastrointest Surg (2005) 1.52
Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone. Gastrointest Endosc (2007) 1.51
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Definition of Barrett's esophagus dysplasia: are we speaking the same language? World J Surg (2015) 1.50
Liver steatosis in children with chronic hepatitis C. Am J Gastroenterol (2006) 1.46
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Intern Emerg Med (2010) 1.40
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics (2013) 1.39
Staging gastritis: an international proposal. Gastroenterology (2005) 1.29
PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch (2011) 1.28
MicroRNA expression profiling of male breast cancer. Breast Cancer Res (2009) 1.22
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) (2007) 1.20
Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol (2012) 1.18
Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl (2009) 1.18
MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer (2011) 1.17
Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol (2013) 1.15
The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation. J Biol Chem (2013) 1.14
Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol (2003) 1.12
Neck emergency due to parathyroid adenoma bleeding: a case report. J Med Case Rep (2009) 1.10
Oxidative DNA damage correlates with cell immortalization and mir-92 expression in hepatocellular carcinoma. BMC Cancer (2012) 1.07
The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol (2006) 1.07
Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer. Surgery (2010) 1.07
Hepatoid adenocarcinoma of the colon: what should we target? Pathol Oncol Res (2011) 1.05
Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. Eur J Cancer Prev (2008) 1.02
Programmed cell death 4 protein in esophageal cancer. Oncol Rep (2010) 1.01
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol (2013) 1.00
Effects of blood group antigen-binding adhesin expression during Helicobacter pylori infection of Mongolian gerbils. J Infect Dis (2011) 0.99
Antibodies against synthetic deamidated gliadin peptides for celiac disease diagnosis and follow-up in children. Clin Chem (2008) 0.99
Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology (2012) 0.98
The ubiquitin ligase Mindbomb 1 coordinates gastrointestinal secretory cell maturation. J Clin Invest (2013) 0.96
BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid (2011) 0.96
Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology (2011) 0.96
MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid (2012) 0.96
Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol (2013) 0.96
Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol (2011) 0.95
Anterior gradient 2 overexpression in lung adenocarcinoma. Appl Immunohistochem Mol Morphol (2012) 0.95
Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood (2011) 0.94
Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res (2006) 0.94
PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Arch (2012) 0.93
Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? Helicobacter (2003) 0.93
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution. Ann Surg Oncol (2011) 0.93
Pathogenesis of Helicobacter pylori infection. Helicobacter (2012) 0.92
Hepatic spleen nodules (HSN). Scand J Gastroenterol (2010) 0.92
Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. Am J Surg Pathol (2004) 0.91
Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol (2004) 0.91
microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6. Gut (2012) 0.91
Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol (2006) 0.91
Oxidative DNA damage in gastric cancer: CagA status and OGG1 gene polymorphism. Int J Cancer (2008) 0.91
BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol (2010) 0.89
Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. Scand J Gastroenterol (2007) 0.89
Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci (2006) 0.89
Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J Clin Pathol (2010) 0.88
The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl Oncol (2013) 0.88
CDX2 hox gene product in a rat model of esophageal cancer. J Exp Clin Cancer Res (2009) 0.88
CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect (2013) 0.88
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget (2013) 0.88
Clinical practice: diagnosis and evaluation of dyspepsia. J Clin Gastroenterol (2010) 0.86
miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol (2011) 0.86
Primary squamous cell carcinoma of the thyroid: immunohistochemical profile and literature review. Tumori (2007) 0.86
Dietary intake of vegetables, folate, and antioxidants and the risk of Barrett's esophagus. Cancer Causes Control (2013) 0.86
Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer. J Clin Oncol (2012) 0.86
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Arch (2014) 0.85
Does Helicobacter pylori infection eradication modify peptic ulcer prevalence? A 10 years' endoscopical survey. World J Gastroenterol (2006) 0.85
5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. Arch Med Res (2006) 0.85
Role of genotyping in non-small cell lung cancer treatment: current status. Drugs (2011) 0.84
Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol (2012) 0.84
Trifluoroacetylated proteins in liver and plasma of guinea pigs treated with HCFC-123 and halothane. Toxicol Lett (2003) 0.84
Comparison of the diagnostic accuracy of combined elastosonography and BRAF analysis vs cytology and ultrasonography for thyroid nodule suspected of malignancy. Clin Endocrinol (Oxf) (2012) 0.84
Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation. Ann Surg Oncol (2013) 0.83
Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype. J Clin Pathol (2007) 0.82
Non-invasive diagnosis of Helicobacter pylori infection: simplified 13C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting? Clin Biochem (2004) 0.82
Magnetic resonance enterography for Crohn's disease: what the surgeon can take home. J Gastrointest Surg (2011) 0.82
Helicobacter pylori infection in children and adults: a single pathogen but a different pathology. Helicobacter (2003) 0.82
Apert syndrome with fused thalami. Fetal Pediatr Pathol (2012) 0.81
Neoangiogenesis in temporal bone carcinoma: the prognostic role of CD105. Otol Neurotol (2012) 0.81
Intestinal or gastric? The unsolved dilemma of Barrett's metaplasia. Hum Pathol (2009) 0.81
Natural course of functional dyspepsia after Helicobacter pylori eradication: a seven-year survey. Dig Dis Sci (2005) 0.81
Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis. Dig Dis (2014) 0.81
Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS One (2011) 0.81
Wilson disease: histopathological correlations with treatment on follow-up liver biopsies. World J Gastroenterol (2010) 0.81
Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy. J Gastrointest Surg (2011) 0.81
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. Clin Chim Acta (2007) 0.81
Helicobacter pylori Infection, Intestinal Metaplasia, and Gastric Cancer Risk in Eastern Siberia. Helicobacter (2011) 0.81
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol (2013) 0.81
Translocation t(11;18)(q21;q21) in gastric B-cell lymphomas. Cancer Sci (2009) 0.80
Esophageal GIST: case report of surgical enucleation and update on current diagnostic and therapeutic options. Int J Surg Pathol (2007) 0.80
Trefoil peptides, E-cadherin, and beta-catenin expression in sporadic fundic gland polyps: further evidence toward the benign nature of these lesions. Appl Immunohistochem Mol Morphol (2009) 0.80
New screening tests enrich anti-transglutaminase results and support a highly sensitive two-test based strategy for celiac disease diagnosis. Clin Chim Acta (2011) 0.80